{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T16:08:22Z","timestamp":1791216502122,"version":"4.1.0"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T00:00:00Z","timestamp":1782086400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Several\n                      <jats:italic>RET<\/jats:italic>\n                      -targeted agents, including highly selective\n                      <jats:italic>RET<\/jats:italic>\n                      inhibitors (SRIs) and multi-kinase inhibitors (MKIs), have been approved for the treatment of advanced medullary thyroid cancer (MTC). Despite these agents targeting the same pathway, direct comparative data is lacking. This study aims to evaluate the relative efficacy and safety of these agents via network meta-analysis (NMA).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We systematically searched PubMed, Embase, Cochrane Library, Web of Science, and CNKI (up to March 2026) for RCTs evaluating\n                      <jats:italic>RET<\/jats:italic>\n                      -targeted therapies for advanced MTC. The primary outcome was progression-free survival (PFS); secondary outcomes included objective response rate (ORR) and \u2265Grade 3 adverse events (AEs). A frequentist random-effects model was employed, and treatments were ranked using P-scores. The study was registered in PROSPERO (CRD420261342793).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Five RCTs (n = 1,076) were included. Selpercatinib demonstrated the most significant PFS benefit (HR = 0.10, 95% CI: 0.05\u20130.18; P-score = 0.999), outperforming cabozantinib (HR = 0.28) and vandetanib (HR = 0.46). It also ranked first for ORR (OR = 122.6, 95% CI: 34.5\u2013435.6). Regarding safety, selpercatinib showed no significant difference in \u2265Grade 3 AEs compared to placebo (OR = 1.34), whereas anlotinib exhibited the highest toxicity (OR = 12.00). Although selpercatinib was associated with hepatotoxicity (OR = 4.20), it avoided the off-target toxicities typical of MKIs, such as hypertension and diarrhea.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This network meta-analysis demonstrates that selpercatinib exhibits superior efficacy (PFS and ORR) and a more favorable safety profile compared to MKIs for advanced MTC. These results support its role as a recommended first-line option for advanced MTC. However, due to the heterogeneity of included populations (mixed RET mutation status and therapy lines), clinicians should interpret these findings with caution regarding the generalizability to strictly defined RET-mutant populations. Clinical decisions should be individualized.<\/jats:p>\n                    <jats:p>\n                      <jats:bold>Systematic review registration:<\/jats:bold>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/PROSPERO\/view\/CRD420261342793<\/jats:ext-link>\n                      , identifier CRD420261342793.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2026.1851074","type":"journal-article","created":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T04:38:10Z","timestamp":1782103090000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Selpercatinib versus multi-kinase inhibitors for advanced medullary thyroid cancer: A network meta-analysis of RET-targeted therapies"],"prefix":"10.3389","volume":"17","author":[{"given":"Jiazhong","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Thyroid Surgery, Second Affiliated Hospital, Xi\u2019an Jiaotong University","place":["Xi\u2019an, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Cao","sequence":"additional","affiliation":[{"name":"Department of Thyroid Surgery, Second Affiliated Hospital, Xi\u2019an Jiaotong University","place":["Xi\u2019an, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Thyroid Surgery, Second Affiliated Hospital, Xi\u2019an Jiaotong University","place":["Xi\u2019an, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Qiao","sequence":"additional","affiliation":[{"name":"Department of Thyroid Surgery, Second Affiliated Hospital, Xi\u2019an Jiaotong University","place":["Xi\u2019an, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiao","family":"He","sequence":"additional","affiliation":[{"name":"Department of Thyroid Surgery, Second Affiliated Hospital, Xi\u2019an Jiaotong University","place":["Xi\u2019an, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of General Surgery, Xi\u2019an Gaoxin Hospital","place":["Xi\u2019an, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1089\/thy.2014.0335","article-title":"Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma","volume":"25","author":"Wells","year":"2015","journal-title":"Thyroid"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2017.175","article-title":"Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes","volume":"15","author":"Drilon","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"3049","DOI":"10.1200\/jco.2011.35.5040","article-title":"Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial (vol 30, pg 134, 2012)","volume":"31","author":"Wells","year":"2013","journal-title":"J Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2022.0027","article-title":"A randomized, double-blind noninferiority study to evaluate the efficacy of the cabozantinib tablet at 60 mg per day compared with the cabozantinib capsule at 140 mg per day in patients with progressive, metastatic medullary thyroid cancer","volume":"32","author":"Capdevila","year":"2022","journal-title":"Thyroid"},{"key":"B5","doi-asserted-by":"publisher","first-page":"3639","DOI":"10.1200\/jco.2012.48.4659","article-title":"Cabozantinib in progressive medullary thyroid cancer","volume":"31","author":"Elisei","year":"2013","journal-title":"J Clin Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/nbt1358","article-title":"A quantitative analysis of kinase inhibitor selectivity","volume":"26","author":"Karaman","year":"2008","journal-title":"Nat Biotechnol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1200\/jco.23.02503","article-title":"Durability of response with selpercatinib in patients with -activated thyroid cancer: long-term safety and efficacy from LIBRETTO-001","volume":"42","author":"Wirth","year":"2024","journal-title":"J Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(21)00247-3","article-title":"Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1\/2 study","volume":"22","author":"Gainor","year":"2021","journal-title":"Lancet Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-20-2950","article-title":"Anlotinib in locally advanced or metastatic medullary thyroid carcinoma: a randomized, double-blind phase IIB trial","volume":"27","author":"Li","year":"2021","journal-title":"Clin Cancer Res"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2016.34.15_suppl.6015","article-title":"Phase II study of anlotinib for treatment of advanced medullary thyroid carcinoma","volume":"34","author":"Sun","year":"2016","journal-title":"J Clin Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.31222\/osf.io\/v7gm2_v1","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"Bmj-Brit Med J"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"Bmj-Brit Med J"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2005651","article-title":"Efficacy of selpercatinib in -altered thyroid cancers","volume":"383","author":"Wirth","year":"2020","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","first-page":"A324","DOI":"10.1016\/j.jval.2014.08.572","article-title":"Evaluating the quality of evidence from a network meta-analysis","volume":"17","author":"Higgins","year":"2014","journal-title":"Value Health"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2024.1403687","article-title":"Safety and efficacy of nintedanib as second-line therapy for patients with differentiated or medullary thyroid cancer progressing after first-line therapy. A randomized phase II study of the EORTC Endocrine Task Force (protocol 1209-EnTF)","volume":"15","author":"Leboulleux","year":"2024","journal-title":"Front Endocrinol"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01469-6","article-title":"Adverse effects of tyrosine kinase inhibitors in cancer therapy: pathophysiology, mechanisms and clinical management","volume":"8","author":"Sunder","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.mtbio.2022.100358","article-title":"Multi-target tyrosine kinase inhibitor nanoparticle delivery systems for cancer therapy","volume":"16","author":"Xu","year":"2022","journal-title":"Mater Today Bio"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00837-z","article-title":"Activity of selpercatinib confirmed in phase III trials","volume":"21","author":"Romero","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.10.059","article-title":"First-line selpercatinib or chemotherapy and pembrolizumab in RET fusion-positive NSCLC","volume":"389","author":"Zhou","year":"2023","journal-title":"N Engl J Med"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1683624","article-title":"Review and analysis of clinical trials of selective RET inhibitors for the treatment of thyroid cancer","volume":"15","author":"Zhou","year":"2025","journal-title":"Front Oncol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1038\/s43018-023-00630-y","article-title":"Vepafestinib is a pharmacologically advanced RET-selective inhibitor with high CNS penetration and inhibitory activity against RET solvent front mutations","volume":"4","author":"Miyazaki","year":"2023","journal-title":"Nat Cancer"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-28848-x","article-title":"The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers (vol 13, 1450, 2022)","volume":"13","author":"Rosen","year":"2022","journal-title":"Nat Commun"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1472008","article-title":"Cardiovascular toxicity risk assessment of tyrosine kinase inhibitors: a pharmacovigilance study using the VigiBase database","volume":"15","author":"Igawa","year":"2024","journal-title":"Front Pharmacol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2018.0022","article-title":"Anlotinib for the treatment of patients with locally advanced or metastatic medullary thyroid cancer","volume":"28","author":"Sun","year":"2018","journal-title":"Thyroid Off J Am Thyroid Assoc"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoto.2025.0542","article-title":"Updated thresholds of basal calcitonin level and extent of lymph node metastasis in initially treated medullary thyroid cancer","volume":"151","author":"Du","year":"2025","journal-title":"JAMA Otolaryngol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1530\/etj-24-0089","article-title":"The role of [18F]F-DOPA PET\/CT in diagnostic and prognostic assessment of medullary thyroid cancer: a 15-year experience with 109 patients","volume":"13","author":"Zhang","year":"2024","journal-title":"Eur Thyroid J"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1097\/rlu.0000000000005558","article-title":"Head-to-head comparison of 68Ga-FAPI-04 and 68Ga-DOTA-TATE PET\/CT in recurrent medullary thyroid cancer","volume":"50","author":"Isik","year":"2024","journal-title":"Clin Nucl Med"},{"key":"B28","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/s2213-8587(15)00337-x","article-title":"Management of advanced medullary thyroid cancer","volume":"4","author":"Hadoux","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"20420188251336091","DOI":"10.1177\/20420188251336091","article-title":"Systemic therapies for medullary thyroid carcinoma: state of the art","volume":"16","author":"Rom\u00e1n-Gonz\u00e1lez","year":"2025","journal-title":"Ther Adv Endocrinol Metab"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1097\/js9.0000000000002816","article-title":"Dynamic risk stratification-guided management of medullary thyroid carcinoma: integrating surgical precision with RET-targeted therapies and molecular surveillance","volume":"111","author":"Zhang","year":"2025","journal-title":"Int J Surg"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1002\/hed.27181","article-title":"Superiority of metastatic lymph node ratio over number of node metastases and TNM\/AJCC N classification in predicting cancer-specific survival in medullary thyroid cancer","volume":"44","author":"Machens","year":"2022","journal-title":"Head Neck"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2021.39.15_suppl.6078","article-title":"A pooled analysis of response to selective RET inhibitors among patients with medullary thyroid cancer with M918T versus non-M918T RET mutations","volume":"39","author":"Kim","year":"2021","journal-title":"J Clin Oncol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1186\/s13044-021-00119-9","article-title":"Diagnostic characteristics, treatment patterns, and clinical outcomes for patients with advanced\/metastatic medullary thyroid cancer","volume":"15","author":"Parikh","year":"2022","journal-title":"Thyroid Res"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2025.08.117","article-title":"Updated efficacy, safety and OS with first-line selpercatinib in advanced RET-mutant medullary thyroid cancer (MTC): LIBRETTO-531","volume":"36","author":"Tahara","year":"2025","journal-title":"Ann Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.07.1736","article-title":"Durable efficacy of selpercatinib in patients (pts) with medullary thyroid cancer (MTC): update of the LIBRETTO-001 trial","volume":"33","author":"Kroiss","year":"2022","journal-title":"Ann Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.d4002","article-title":"Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials","volume":"343","author":"Sterne","year":"2011","journal-title":"Bmj-Brit Med J"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.01.006","article-title":"Solvent front mutations mediate acquired resistance to selective inhibition in -driven Malignancies","volume":"15","author":"Solomon","year":"2020","journal-title":"J Thorac Oncol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.10.599","article-title":"Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations","volume":"32","author":"Subbiah","year":"2021","journal-title":"Ann Oncol"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.09.015","article-title":"Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer","volume":"31","author":"Lin","year":"2020","journal-title":"Ann Oncol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1177\/10507256261416836","article-title":"Liquid biopsy-based mutation profiling to guide inhibitor treatment in sporadic medullary thyroid carcinoma may be useful in cases with high tumor burden and progressive disease","volume":"36","author":"Ciampi","year":"2026","journal-title":"Thyroid"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.cd-18-0444","article-title":"SHP2 inhibition prevents adaptive resistance to MEK inhibitors in multiple cancer models","volume":"8","author":"Fedele","year":"2018","journal-title":"Cancer Discov"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1851074\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,22]],"date-time":"2026-06-22T04:38:20Z","timestamp":1782103100000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1851074\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,22]]},"references-count":41,"alternative-id":["10.3389\/fendo.2026.1851074"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1851074","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,22]]},"article-number":"1851074"}}